EUVIMEDEUVIMED entdecken
Open Access

Biological Activities of Etodolac‐Based Hydrazone, Thiazolidinone and Triazole Derivatives on Breast Cancer Cell Lines MCF‐7 and MDA‐MB‐231

Sevgi Kocyigit Sevinc iD, Pelin Çıkla-Süzgün, Pinar Mega Tiber iD, Ş Güniz Küçükgüzel, Oya Orun

Journal of Biochemical and Molecular Toxicology · 2025

DOI: 10.1002/jbt.70428 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Sevgi Kocyigit Sevinc und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics, Faculty of Medicine, Marmara University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Thiazolidines, Etodolac, Triazoles, Hydrazones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: This study was supported by the Scientific Research Project Commission of Marmara University (Project Number: SAG-C-DRP-100914-0321). The funding provided esse….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, several etodolac‐based hydrazone, thiazolidinone, and triazole derivatives that we synthesized and characterized in our earlier research were tested against the hormone‐responsive breast cell line MCF‐7 and the triple‐negative MDA‐MB‐231, as well as the murine origin fibroblast cell line L‐929, at varying doses for their effects on cell viability and toxicity and for their inhibitory activity on cyclooxygenase‐2 (COX‐2)/prostaglandin E2 (PGE2) formation. Cell viability and apoptosis tests were utilized to assess the anti‐cancer potential of etodolac and its derivatives after the cells were exposed to varied concentrations of synthesized compounds for three different time periods. ELISA and Western blot methods were used to detect protein levels. All synthesized compounds demonstrated higher anti‐cancer activity at significantly lower doses compared to etodolac (half‐maximal inhibitory concentration [IC50] of 0‐50 µM range in derivatives versus 0.5−1 mM range in etodolac). Except for SGK 242, which had a major toxic effect on all cells, the chemicals SGK 206 and SGK 217 had a twice‐less impact on control murine L‐929 fibroblasts. Similar to proliferation, low concentrations of SGK 206 and SGK 217 (25−50 µM) significantly induced apoptosis in breast cancer cells but not in normal cells. Additionally, they inhibited COX‐2 protein expression at 50 µM, and SGK 206 inhibited PGE2 release more effectively than etodolac in cancer cells. The results of this study suggest that, in comparison to a healthy control group, the thiazolidinone derivative SGK 206 and the thiazolidinone derivative SGK 217 are more effective than etodolac when it comes to the breast cancer cell lines MCF‐7 and MDA‐MB‐231. SGK 206 exhibits a low IC50 value, a distinct dose–response relationship, and strong apoptotic effects, particularly on MDA‐MB‐231 cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiazolidinesEtodolacTriazolesHydrazonesBreast NeoplasmsAntineoplastic AgentsHumansMCF-7 CellsFemaleApoptosisMiceAnimalsDinoprostoneCyclooxygenase 2Cell Survival

Stichwörter der Autor:innen

apoptosisbreast cancercell viabilitycyclooxygenaseetodolacprostaglandin E2

Substanzen

ThiazolidinesEtodolacTriazolesHydrazonesDinoprostoneCyclooxygenase 2Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Biophysics, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Department of Biophysics, Faculty of Medicine, Kütahya Health Sciences University, Kütahya, Turkey.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Istanbul, Turkey.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Fenerbahce University, Istanbul, Turkey.

ORCID-Profile: Sevgi Kocyigit Sevinc, Pinar Mega Tiber

Förderung

  • This study was supported by the Scientific Research Project Commission of Marmara University (Project Number: SAG-C-DRP-100914-0321). The funding provided esse…

Zitieren

APA

Sevinc, S. K., Çıkla-Süzgün, P., Tiber, P. M., Güniz Küçükgüzel, Ş., & Orun, O. (2025). Biological Activities of Etodolac‐Based Hydrazone, Thiazolidinone and Triazole Derivatives on Breast Cancer Cell Lines MCF‐7 and MDA‐MB‐231. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70428

Vancouver

Sevinc SK, Çıkla-Süzgün P, Tiber PM, Güniz Küçükgüzel Ş, Orun O. Biological Activities of Etodolac‐Based Hydrazone, Thiazolidinone and Triazole Derivatives on Breast Cancer Cell Lines MCF‐7 and MDA‐MB‐231. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70428

BibTeX
@article{Sevinc2025,
  author = {Sevinc, Sevgi Kocyigit and Çıkla-Süzgün, Pelin and Tiber, Pinar Mega and Güniz Küçükgüzel, Ş and Orun, Oya},
  title = {Biological Activities of Etodolac‐Based Hydrazone, Thiazolidinone and Triazole Derivatives on Breast Cancer Cell Lines MCF‐7 and MDA‐MB‐231},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2025},
  doi = {10.1002/jbt.70428}
}
Kostenlos starten →